IRIS
PIRISI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.879
NA - Nord America 6.826
AS - Asia 2.236
SA - Sud America 29
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 11
Totale 18.027
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.755
IE - Irlanda 2.757
IT - Italia 1.398
SE - Svezia 1.270
DE - Germania 1.136
UA - Ucraina 887
FR - Francia 659
HK - Hong Kong 602
CN - Cina 556
SG - Singapore 500
FI - Finlandia 393
IN - India 310
CZ - Repubblica Ceca 129
GB - Regno Unito 104
CA - Canada 67
VN - Vietnam 64
IR - Iran 55
TR - Turchia 47
BE - Belgio 44
KR - Corea 22
NL - Olanda 22
EU - Europa 20
PK - Pakistan 14
RU - Federazione Russa 14
JP - Giappone 13
CH - Svizzera 10
EG - Egitto 10
AU - Australia 9
CL - Cile 9
LT - Lituania 9
PL - Polonia 9
PE - Perù 8
RO - Romania 8
MY - Malesia 7
PH - Filippine 7
KE - Kenya 6
BD - Bangladesh 5
BR - Brasile 5
ES - Italia 5
CO - Colombia 4
ID - Indonesia 4
MO - Macao, regione amministrativa speciale della Cina 4
PT - Portogallo 4
SA - Arabia Saudita 4
TW - Taiwan 4
ZA - Sudafrica 4
GR - Grecia 3
IL - Israele 3
NO - Norvegia 3
TH - Thailandia 3
AR - Argentina 2
AT - Austria 2
BG - Bulgaria 2
CU - Cuba 2
IQ - Iraq 2
LI - Liechtenstein 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
CY - Cipro 1
EC - Ecuador 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
PA - Panama 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
UZ - Uzbekistan 1
Totale 18.027
Salva come PNG Salva come JPEG
Città #
Dublin 2.739
Jacksonville 1.663
Dearborn 737
Chandler 604
Hong Kong 588
Wilmington 432
Singapore 343
Princeton 334
Lawrence 333
San Mateo 252
Novara 246
Ann Arbor 241
Beijing 238
Piemonte 216
Ashburn 163
Andover 130
Boardman 104
Milan 104
Munich 81
Houston 77
Brno 73
Woodbridge 71
Turin 68
Vercelli 67
Bremen 65
Dong Ket 60
Nanjing 56
Hefei 49
Helsinki 44
Brussels 42
Philadelphia 39
Düsseldorf 38
Norwalk 33
Pardubice 32
Kunming 28
Kocaeli 27
Santa Clara 27
Seattle 25
Toronto 24
Torino 23
Monmouth Junction 20
Rome 20
Mülheim 19
Fairfield 18
Jinan 18
Nanchang 18
Alessandria 17
Strasbourg 17
Ardabil 16
Cassano Magnago 16
Guangzhou 16
Frankfurt am Main 15
Leawood 15
Los Angeles 15
West Jordan 14
Zanjan 14
České Budějovice 14
Augusta 13
Grafing 13
Palermo 13
Chennai 12
London 10
Ottawa 10
Paris 10
Shenyang 10
Zhengzhou 10
Fuzhou 9
New York 9
Odalengo Grande 9
Villa Cortese 9
Alba 8
Bologna 8
Lancenigo-Villorba 8
Montreal 8
Redwood City 8
Suwon 8
Zurich 8
Amsterdam 7
Berlin 7
Brescia 7
Genoa 7
Royal Leamington Spa 7
Sham Shui Po 7
Shanghai 7
Stankov 7
Wuhan 7
Borgomanero 6
Nairobi 6
Verona 6
Bari 5
Cambridge 5
Chimbote 5
Espoo 5
Hebei 5
Kraków 5
Menlo Park 5
Naples 5
Ningbo 5
Stresa 5
Vancouver 5
Totale 11.127
Salva come PNG Salva come JPEG
Nome #
Midterm functional sequelae and implications in rehabilitation after COVID19. A cross-sectional study 242
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 145
Role of beta-blockers in patients with COPD: current perspective. 110
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 104
Testosterone Plasma Concentration is Associated with Insulin Resistance in Male Hypertensive Patients 101
Genistein and 17β-Estradiol Protect Hepatocytes from Fatty Degeneration by Mechanisms Involving Mitochondria, Inflammasome and Kinases Activation 100
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 97
Change over time of COVID-19 hospital presentation in Northern Italy 96
Gas6 as a predictor of esophageal varices in patients affected by hepatitis C virus related-chronic liver disease 95
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 95
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 94
Liver infection and COVID-19: the electron microscopy proof and revision of the literature 91
Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay. 85
Antiviral treatment of hepatitis C improves glucose metabolism along the entire spectrum from normal glucose tolerance to diabetes 83
rs1801253 Gly/Gly carriage in the ADRB1 gene leads to unbalanced cardiac sympathetic modulation as assessed by spectral analysis of heart rate variability 81
Gas6/TAM system: A key modulator of the interplay between inflammation and fibrosis 80
Red cell distribution width and platelet count as biomarkers of pulmonary arterial hypertension in patients with connective tissue disorders 80
Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. 79
Influence of age on sex-related differences among patients with hepatitis C. 79
Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma 79
Prediction of serum markers of fibrosis by levels of circulating intercellular adhesion molecule-1 in acute and chronic liver disease 77
Pattern of emergency department referral during the Covid-19 outbreak in Italy 77
Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis 76
Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C 75
Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study. 75
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19 75
17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle 74
Acute decompensated heart failure in the emergency department: Identification of early predictors of outcome 74
Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease 73
Association between rheumatic diseases and cancer: results from a clinical practice cohort study 73
Is cholecalciferol a potential disease modifying anti-rheumatic drug for the management of rheumatoid arthritis? 73
Association between red cell distribution width and response to methotrexate in rheumatoid arthritis 73
Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease is predicted by circulating levels of adhesion molecules 72
Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis 72
Prediction of jaundice by markers of inflammation in patients with liver disease 71
Reactivity to B cell epitopes within hepatitis C virus core protein and hepatocellular carcinoma 71
Analysis of beta1 and beta2-adrenergic receptors polymorphism in patients with apical ballooning cardiomyopathy 70
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 70
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 69
Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment 69
Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge 69
One-Year Follow up of Noninvasive Respiratory Support in General Wards 68
High prevalence of infection with hapatitis G virus in patients with hepatic and extrahepatic malignancies 68
Association between vitamin D receptor genetic polymorphisms and acute cellular rejection in liver-transplanted patients 68
Diagnostic value of FibroTest with normal serum aminotransferases 68
Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents 68
(Letter) Membranoproliferative glomerulonephritis associated with Hepatitis C infection with no evidence of liver disease 67
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 67
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 67
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 67
Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis 67
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 67
Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. 66
Ultrasound-assessed visceral fat and associations with glucose homeostasis and cardiovascular risk in clinical practice 66
Increased plasma levels of Gas6 and its soluble tyrosine kinase receptors Mer and Axl are associated with immunological activity and severity of lupus nephritis 66
Oxidative Stress in Non-Alcoholic Fatty Liver Disease 66
Natural history and risk stratification of patients undergoing non-invasive ventilation in a non-ICU setting for severe COPD exacerbations 65
Outcomes of COVID-19 patients treated with continuous positive airway pressure outside ICU 65
Circulating intercellular adhesion molecule-1 (clCAM-1) concentration in liver disease 64
Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma 64
Peroxisome proliferator-activated receptor-gamma expression in monocytes/macrophages from rheumatoid arthritis patients: relation to disease activity and therapy efficacy--a pilot study 64
Severity of nonalcoholic fatty liver disease in type 2 diabetes mellitus: Relationship between nongenetic factors and PNPLA3/HSD17B13 polymorphisms 64
Endotoxin priming worsens acute reflux pancreatitis in the rat 63
Gas6 as a putative noninvasive biomarker of hepatic fibrosis 63
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 63
Thrombocytopenia in chronic liver disease corrected by erithropoietin treatment 62
Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease 62
Evidence against a direct role played by transfusion-transmitted virus infection in causing hepatic or hematologic manifestations 62
Endotoxin priming and liver damage by experimental duodenal obstruction in the rat 62
Impaired glucose metabolism in hypertensive patients with/without the metabolic syndrome. 62
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 62
4. Association between release of tumor necrosis factor and response to interferon therapy in chronic hepatitis C 62
Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C 62
Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on β1 and β2-adrenergic receptors polymorphisms? 62
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 62
Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma 62
Hypeglycaemia-induced thrombin formation in Diabetes. The possible role of oxydative stress 61
Evidence for a multifactorial control of serum erythropoietin concentration in liver disease 61
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C 61
Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts 61
Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C 61
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 61
Significato e valore diagnostico dei sintomi e degli esami di laboratorio 61
Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review 61
Immune suppressive treatment of Berger disease 60
Letter. Activation of the endogenous interferon sustem, expression of interferon-alpha receptors, and response to interferon therapy in chronic hepatitis C 60
Asymptomatic HBV and HCV carriers, bad breath and gengivitis 60
IL28B Polymorphism, Blood Interferon-alpha Concentration, and Disease Stage of HCV Mono-infected and HCV-HIV Co-infected Patients. 60
Fibrosis Progression in HCV Carriers with Mild Hepatitis Who Possess the High-Repetition Variant of the DRD4 Gene, a Genetic Marker for Binge-Drinking and Risk-Seeking Behavior: A Longitudinal Study. 60
Combinatorial use of single nucleotide polymorphisms to help predict liver fibrosis in patients with hepatitis C infections 60
AORTIC INVOLVEMENT IN A RETROSPECTIVE COHORT OF LARGE VESSEL VASCULITIS PATIENTS 60
Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor 60
"war to the knife" against thromboinflammation to protect endothelial function of COVID-19 patients 60
Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients 60
Diagnostic usefulness of acute phase protein measurement in hepatocellular carcinoma 59
Fatal human pulmonary infection caused by an Angiostrongylus-like nematode 59
Immunosoppressive treatment for idiopathic nephrotic syndrome with corticosteroids and cyclophosphamide 59
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. 59
Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of the AST to platelet ratio index 59
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C 59
Totale 7.249
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.593
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.593
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.541 0 0 0 0 0 456 652 192 415 480 323 23
2020/20212.295 299 7 303 14 327 97 318 50 327 77 364 112
2021/20222.292 101 58 459 229 113 28 168 80 196 104 286 470
2022/20235.506 503 221 277 151 299 446 166 229 2.836 34 223 121
2023/20242.585 140 344 150 76 392 74 484 134 54 86 250 401
2024/2025877 134 66 264 144 147 122 0 0 0 0 0 0
Totale 18.628